Survival of adults with systemic sclerosis following lung transplantation: A nationwide cohort study

Arthritis and Rheumatology

Volumn 67, Issue 5, 2015, Pages 1314-1322

  Bernstein, Elana J ^a   Peterson, Eric R ^b   Sell, Jessica L ^b   D'Ovidio, Frank ^b   Arcasoy, Selim M ^b   Bathon, Joan M ^a   Lederer, David J ^b  

^a College of Physicians and Surgeons ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; ESOPHAGUS DISEASE; EXTRACORPOREAL OXYGENATION; FEMALE; GASTROESOPHAGEAL REFLUX; GRAFT RECIPIENT; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORGAN DONOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REFLUX ESOPHAGITIS; RETROSPECTIVE STUDY; RISK FACTOR; STOMACH PARESIS; SURVIVAL; SYSTEMIC SCLEROSIS; COMPARATIVE STUDY; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCLERODERMA, SYSTEMIC; SURVIVAL RATE;

ADULT; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SURVIVAL RATE;

EID: 84928637159     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39021     Document Type: Article

References (49)

1. Massad MG, Powell CR, Kpodonu J, Tshibaka C, Hanhan Z, Snow NJ, et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg 2005; 29: 1510-5.
2. Rosas V, Conte JV, Yang SC, Gaine SP, Borja M, Wigley FM, et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000; 5: 38-43.
3. Khan IY, Singer LG, de Perrot M, Granton JT, Keshavjee S, Chau C, et al. Survival after lung transplantation in systemic sclerosis: a systematic review. Respir Med 2013; 107: 2081-7.
4. Shitrit D, Amital A, Peled N, Raviv Y, Medalion B, Saute M, et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant 2009; 23: 178-83.
5. Saggar R, Khanna D, Furst DE, Belperio JA, Park GS, Weigt SS, et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J 2010; 36: 893-900.
6. Schachna L, Medsger TA Jr, Dauber JH, Wigley FM, Braunstein NA, White B, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54: 3954-61.
7. Egan TM, Murray S, Bustami RT, Shearon TH, McCullough KP, Edwards LB, et al. Development of the new lung allocation system in the United States. Am J Transplant 2006; 6: 1212-27.
8. Liu V, Zamora MR, Dhillon GS, Weill D., Increasing lung allocation scores predict worsened survival among lung transplant recipients. Am J Transplant 2010; 10: 915-20.
9. Weiss ES, Allen JG, Merlo CA, Conte JV, Shah AS., Lung allocation score predicts survival in lung transplantation patients with pulmonary fibrosis. Ann Thorac Surg 2009; 88: 1757-64.
10. United Network for Organ Sharing. A guide to calculating the lung allocation score. URL: http://www.unos.org/docs/lung-allocation-score.pdf.
11. Azur MJ, Stuart EA, Frangakis C, Leaf PJ., Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res 2011; 20: 40-9.
12. Rubin DB., Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons; 1997.
13. Rubin DB, Schenker N., Multiple imputation in health-care databases: an overview and some applications. Stat Med 1991; 10: 585-98.
14. Lakatos E., Designing complex group sequential survival trials. Stat Med 2002; 21: 1969-89.
15. Lakatos E., Sample sizes based on the log-rank statistic in complex clinical trials [published erratum appears in Biometrics 1988;44:923]. Biometrics 1988; 44: 229-41.
16. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-50.
17. Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012; 71: 249-52.
18. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE., Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-50.
19. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
20. Abbassi-Ghadi N, Kumar S, Cheung B, McDermott A, Knaggs A, Zacharakis E, et al. Anti-reflux surgery for lung transplant recipients in the presence of impedance-detected duodenogastroesophageal reflux and bronchiolitis obliterans syndrome: a study of efficacy and safety. J Heart Lung Transplant 2013; 32: 588-95.
21. Murthy SC, Nowicki ER, Mason DP, Budev MM, Nunez AI, Thuita L, et al. Pretransplant gastroesophageal reflux compromises early outcomes after lung transplantation. J Thorac Cardiovasc Surg 2011; 142: 47-52.e3.
22. Cantu E III, Appel JZ III, Hartwig MG, Woreta H, Green C, Messier R, et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004; 78: 1142-51.
23. Davis RD Jr, Lau CL, Eubanks S, Messier RH, Hadjiliadis D, Steele MP, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125: 533-42.
24. Hartwig MG, Anderson DJ, Onaitis MW, Reddy S, Snyder LD, Lin SS, et al. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann Thorac Surg 2011; 92: 462-8.
25. Hugle T, Hogan V, White KE, van Laar JM., Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum 2011; 63: 795-9.
26. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008; 58: 1465-74.
27. O'Reilly S,. Innate immunity in systemic sclerosis pathogenesis. Clin Sci (Lond) 2014; 126: 329-37.
28. Kim D, Peck A, Santer D, Patole P, Schwartz SM, Molitor JA, et al. Induction of interferon-α by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-α activity with lung fibrosis. Arthritis Rheum 2008; 58: 2163-73.
29. Eloranta ML, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom A, Rubin K, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010; 69: 1396-402.
30. Farina G, Lafyatis D, Lemaire R, Lafyatis R., A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010; 62: 580-8.
31. Kreisel D, Goldstein DR., Innate immunity and organ transplantation: focus on lung transplantation. Transpl Int 2013; 26: 2-10.
32. Verleden SE, Ruttens D, Vos R, Vandermeulen E, Moelants E, Mortier A, et al. Differential cytokine, chemokine and growth factor expression in phenotypes of chronic lung allograft dysfunction. Transplantation 2015; 99: 86-93.
33. Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009; 11: R111.
34. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K., Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998; 25: 296-301.
35. Lee EB, Zhao J, Kim JY, Xiong M, Song YW., Evidence of potential interaction of chemokine genes in susceptibility to systemic sclerosis. Arthritis Rheum 2007; 56: 2443-8.
36. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, et al. CXCL10 (α) and CCL2 (β) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford) 2008; 47: 45-9.
37. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S., Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011; 30: 231-7.
38. Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL., Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001; 44: 1382-6.
39. Distler O, Pignone A., Pulmonary arterial hypertension and rheumatic diseases-from diagnosis to treatment. Rheumatology (Oxford) 2006; 45 Suppl 4: iv22-5.
40. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001; 44: 2665-78.
41. Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD., Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998; 114: 293-300.
42. Yamamoto T, Eckes B, Hartmann K, Krieg T., Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001; 26: 133-9.
43. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM., Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997; 40: 743-51.
44. Hasegawa M, Sato S, Takehara K,. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999; 117: 159-65.
45. Grigoryev DN, Mathai SC, Fisher MR, Girgis RE, Zaiman AL, Housten-Harris T, et al. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res 2008; 151: 197-207.
46. Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 2003; 48: 1979-91.
47. Yanaba K, Komura K, Kodera M, Matsushita T, Hasegawa M, Takehara K, et al. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis 2006; 65: 124-6.
48. Prasse A, Pechkovsky DV, Toews GB, Schafer M, Eggeling S, Ludwig C, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007; 56: 1685-93.
49. Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S., Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 2005; 52: 2889-96.